Homepage
Medication Guide
What Are the Side Effects of Aduhelm (Aducanumab)?
Aduhelm (Aducanumab) is the first monoclonal antibody drug targeting beta-amyloid plaques in Alzheimer's disease to receive accelerated approval from the U.S. FDA. It is indicated for patients wit...
507
Tuesday, September 16th, 2025, 16:32
Indications for Talquetamab
Talquetamab is a bispecific T-cell engager targeting GPRC5D and CD3. It received accelerated approval from the U.S. FDA in 2023 for the treatment of relapsed or refractory multiple myeloma.Indications...
511
Tuesday, September 16th, 2025, 16:29
How to Administer Talquetamab
Talquetamab is a CD3 T-cell bispecific antibody targeting GPRC5D, indicated for the treatment of relapsed or refractory multiple myeloma. As a novel immunotherapy, its administration methods and preca...
515
Tuesday, September 16th, 2025, 16:27
Precautions for the Administration of Talquetamab
Talquetamab is a GPRC5D/CD3 bispecific antibody approved by the U.S. FDA in 2023 for the treatment of relapsed or refractory multiple myeloma.Precautions for the Administration of TalquetamabConfirmat...
511
Tuesday, September 16th, 2025, 16:24
How to Use Talquetamab
Talquetamab is a CD3 T-cell bispecific antibody targeting GPRC5D, indicated for the treatment of relapsed or refractory multiple myeloma. As a novel immunotherapy, its administration methods and preca...
515
Tuesday, September 16th, 2025, 16:22
Important Precautions for the Use of Talquetamab
Talquetamab is a GPRC5D/CD3 bispecific antibody approved by the U.S. FDA in 2023 for the treatment of relapsed or refractory multiple myeloma.Important Precautions for the Use of TalquetamabIndication...
514
Tuesday, September 16th, 2025, 16:19
How to Use Imdelltra (Tarlatamab)
Imdelltra (tarlatamab) is a bispecific T-cell engager targeting DLL3-CD3. It received accelerated approval from the U.S. FDA in 2024 for the treatment of extensive-stage small cell lung cancer (ES-SCL...
523
Tuesday, September 16th, 2025, 16:17
Precautions for Imdelltra (Tarlatamab) Administration
Imdelltra (tarlatamab) is a bispecific T-cell engager targeting DLL3/CD3, indicated for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) that has progressed after platinum-based chemo...
517
Tuesday, September 16th, 2025, 16:14
Precautions for Revuforj (Revumenib) Administration
Revuforj (revumenib) is a targeted menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene translocation. As an innovative targeted drug, its unique mechan...
513
Tuesday, September 16th, 2025, 16:11
How to Use Aduhelm (Aducanumab)
Aduhelm (aducanumab) is a monoclonal antibody targeting amyloid beta, used for the treatment of Alzheimer's disease. As the first disease-modifying therapy for Alzheimer's disease to receive a...
510
Tuesday, September 16th, 2025, 16:08
129 / 221
2204 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved